Enovis Corporation (ENOV) Stock Score, Valuation & Financial Research
Enovis Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for ENOV
Enovis Corporation currently has a Wall Street Score of 20/100. The stored market price is $17.94. Its financial score is 21/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Enovis Corporation does
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a com
ENOV financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $17.94
- Market capitalization:
- $1.03B
- Revenue:
- $2.30B
- Net income:
- $-1.10B
- Free cash flow:
- $19.9M
- Cash:
- $12.6M
- Total debt:
- $1.37B
- EPS:
- -19.40
- Financial score:
- 21/100
- Valuation score:
- 0/100
- Revenue score:
- 34/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $19.9M, showing positive cash generation.
- The balance sheet shows $12.6M of cash versus $1.37B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 21/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research ENOV
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.